Balwinder Singh, MD, MS

Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota

12Articles
144.8KReads
2016–2026Active
39Collaborators
303Citations

About

Balwinder Singh, MD, MS is affiliated with Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota. Balwinder Singh has authored or co-authored 11 peer-reviewed articles published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders between 2016 and 2026. Their work focuses on Depression (MDD), Addiction, Anxiety, Posttraumatic Stress Disorder, and Psychedelics.

Publications

Letter to the Editor

Psychotherapy, Pharmacotherapy, and Neuromodulatory Interventions in Operational Definitions of TRD: Reply to De Oliveira Reis et al

August 19, 2026

Marques et al reply to commentary on their consensus-based recommendations for treatment-resistant depression.

Matheus G. Marques, Mark A. Frye, Balwinder Singh

Consensus Statement

Next-Step Treatment Options for Treatment-Resistant Depression

January 21, 2026

Strong consensus emerged for augmentation with second-generation antipsychotics, TMS, and ketamine/esketamine in the base vignette. Preferences shifted to include non-augmentative antidepressants and ECT based on patient characteristics.

Matheus G. Marques, Aysegul Özerdem, Simon Kung, et al

Original Research

Ketamine Reduces Suicidality Associated ED Use in Patients With Treatment-Resistant Depression

September 17, 2025

After the acute phase of ketamine treatment, ED visits for suicidal ideation decreased by 84%, and total ED visits for suicidality decreased by 63%.

Liliana Patarroyo-Rodriguez, Vanessa K. Pazdernik, Jennifer L. Vande Voort, et al

$Long-Term Outcomes of IV Ketamine and IN Esketamine in Treatment-Refractory Depression$

Original Research

Long-Term Outcomes of IV Ketamine and IN Esketamine in Treatment-Refractory Depression

July 30, 2025

The study results suggest that patients with treatment-resistant depression who are on maintenance treatment require less frequent treatments with IV ketamine compared to IN esketamine.

Balwinder Singh, Vanessa K. Pazdernik, Simon Kung, et al

Case Report

SSRI Discontinuation and AUD Relapse

August 26, 2024

A man with AUD achieves sobriety on treatment with an SSRI and naltrexone, but then stops taking the SSRI to participate in a psilocybin “ceremony.” What factors contributed to...

Mark A. Frye, Balwinder Singh, Scott A. Breitinger, et al

ASCP Corner

When and How to Use Lithium Augmentation for MDD

March 8, 2023

With its antisuicidal effect and low cost, lithium can be an effective alternative to other MDD augmentation strategies when antidepressants are not enough.

Mete Ercis, Ayşegül Özerdem, Balwinder Singh

Original Research

Ketamine vs Esketamine for TRD

February 1, 2023

Are ketamine and esketamine equally efficacious? This observational study compares the efficacy of subanesthetic intravenous ketamine with that of intranasal esketamine for treatment-resistant depression in a real-world clinical setting.

Balwinder Singh, Simon Kung, Vanessa Pazdernik, et al

ASCP Corner

Thyroid Hormone Use in Mood Disorders

August 15, 2022

This ASCP Corner article reviews the potential benefits and harms of thyroid hormone therapy in the management of unipolar and bipolar depression.

Balwinder Singh, Vishnu Sundaresh

Meta-Analysis

Adjunctive Aripiprazole for MDD

June 24, 2021

Given the scarcity of data, the authors of this review systematically synthesized the literature to determine the long-term efficacy and safety of aripiprazole as a maintenance augmenting agent for...

Balwinder Singh, Ashok Seshadri, Michaela E. Wermers, et al

Review Article

Exercise, Yoga, and Tai Chi for Depression

December 31, 2020

Exercise, yoga, and tai chi are commonly used complementary approaches for health and wellness. This review aims to synthesize the evidence for exercise, yoga, and tai chi in the...

Mark A. Frye, Balwinder Singh, Ashok Seshadri, et al

Letter to the Editor

BMI and Remission in Depressed Patients Receiving IV Ketamine

November 12, 2019

Few studies have evaluated optimal dosing of intravenous (IV) ketamine for treatment-resistant depression (TRD). This report analyzes data from previous studies of IV ketamine to assess the association between...

Mark A. Frye, Keith G. Rasmussen, William V. Bobo, et al

Article

Efficacy of Prazosin in PTSD

July 28, 2016

Prazosin is an emerging treatment modality for the debilitating symptoms of PTSD. But, while the evidence of its effectiveness and efficacy is promising, it is not definitive. The authors...

Balwinder Singh, Andrew J. Hughes, Gaurav Mehta, et al

Areas of focus

Depression (MDD) Addiction Anxiety Posttraumatic Stress Disorder Psychedelics Psychopharmacology Suicide

Frequent collaborators

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Balwinder Singh, MD, MS

About

Publications

Psychotherapy, Pharmacotherapy, and Neuromodulatory Interventions in Operational Definitions of TRD: Reply to De Oliveira Reis et al

Next-Step Treatment Options for Treatment-Resistant Depression

Ketamine Reduces Suicidality Associated ED Use in Patients With Treatment-Resistant Depression